WEKO3
アイテム
{"_buckets": {"deposit": "c1a5e23d-3f09-4abc-83b3-3ccc3caadba9"}, "_deposit": {"created_by": 2, "id": "22591", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "22591"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00022591", "sets": ["1609"]}, "author_link": ["96102", "96104", "96103"], "item_3_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2005-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "supl.1", "bibliographicPageEnd": "95", "bibliographicPageStart": "91", "bibliographicVolumeNumber": "50", "bibliographic_titles": [{"bibliographic_title": "Acta medica Nagasakiensia"}]}]}, "item_3_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells characterized by ineffective and inadequate hematopoiesis. MDS in a subset of patients arise after previous chemotherapy or radiation exposure for other malignancies. As MDS is a heterogeneous disorder, specific gene abnormalities playing a role in the myelodysplastic process have been difficult to identify. In this study, we analyzed the somatic mutations in the AML1/RUNX1 gene, which is a critical regulator of definitive hematopoiesis and the most frequent targets for translocation of acute myeloid leukemia (AML), in patients with MDS. We detected AML1 point mutations in 26 of 110 (23.6%) patients with refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEBt) and AML following MDS (defined these categories as MDS/AML). Among 22 patients with radiation-related (including 14 atomic bomb survivors) and/or therapy-related MDS/AML, 11 (50%) patients had the AML1 mutations mostly in N-terminal region. In contrast, 15 of 88 (17%) patients with sporadic MDS/AML showed the AML1 mutations equally in both N-terminal and C-terminal region. The MDS/AML patients with AML1 mutations had a significantly worse prognosis than those without AML1 mutations. Most of AML1 mutants lost trans-activation potential, regardless of their DNA binding potential. These data suggested that AML1 point mutation is one of the major driving forces of MDS/AML, and these mutations may represent a distinct clinicopathologic-genetic entity.", "subitem_description_type": "Abstract"}]}, "item_3_description_64": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Acta medica Nagasakiensia. 2005, 50(supl.1), p.91-95", "subitem_description_type": "Other"}]}, "item_3_relation_42": {"attribute_name": "関係URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "http://joi.jlc.jst.go.jp/JST.JSTAGE/amn/50.S91"}]}]}, "item_3_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00508430", "subitem_source_identifier_type": "NCID"}]}, "item_3_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00016055", "subitem_source_identifier_type": "ISSN"}]}, "item_3_text_62": {"attribute_name": "sortkey", "attribute_value_mlt": [{"subitem_text_value": "P00091-P00095"}]}, "item_3_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Harada, Hironori"}], "nameIdentifiers": [{"nameIdentifier": "96102", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Harada, Yuka"}], "nameIdentifiers": [{"nameIdentifier": "96103", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kimura, Akiro"}], "nameIdentifiers": [{"nameIdentifier": "96104", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "acta50_s1_91.pdf", "filesize": [{"value": "708.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 708400.0, "url": {"label": "acta50_s1_91.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/22591/files/acta50_s1_91.pdf"}, "version_id": "ac2404c3-f5f0-4678-a97d-d2725ebcf481"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Myelodysplasticsyndrome(MDS)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "AML1/RUNX1", "subitem_subject_scheme": "Other"}, {"subitem_subject": "MDS/AML", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Genomicinstability", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Runtdomain", "subitem_subject_scheme": "Other"}, {"subitem_subject": "SecondaryMDS/AML", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Point Mutations in the AML1/RUNX1 Gene Associated with Myelodysplastic Syndrome (MDS)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Point Mutations in the AML1/RUNX1 Gene Associated with Myelodysplastic Syndrome (MDS)"}]}, "item_type_id": "3", "owner": "2", "path": ["1609"], "permalink_uri": "http://hdl.handle.net/10069/9319", "pubdate": {"attribute_name": "公開日", "attribute_value": "2007-11-02"}, "publish_date": "2007-11-02", "publish_status": "0", "recid": "22591", "relation": {}, "relation_version_is_last": true, "title": ["Point Mutations in the AML1/RUNX1 Gene Associated with Myelodysplastic Syndrome (MDS)"], "weko_shared_id": -1}
Point Mutations in the AML1/RUNX1 Gene Associated with Myelodysplastic Syndrome (MDS)
http://hdl.handle.net/10069/9319
http://hdl.handle.net/10069/93198a1b1103-4300-41ba-955b-338092cb2765
名前 / ファイル | ライセンス | アクション |
---|---|---|
acta50_s1_91.pdf (708.4 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2007-11-02 | |||||
タイトル | ||||||
タイトル | Point Mutations in the AML1/RUNX1 Gene Associated with Myelodysplastic Syndrome (MDS) | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Myelodysplasticsyndrome(MDS) | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | AML1/RUNX1 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | MDS/AML | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Genomicinstability | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Runtdomain | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | SecondaryMDS/AML | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
著者 |
Harada, Hironori
× Harada, Hironori× Harada, Yuka× Kimura, Akiro |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells characterized by ineffective and inadequate hematopoiesis. MDS in a subset of patients arise after previous chemotherapy or radiation exposure for other malignancies. As MDS is a heterogeneous disorder, specific gene abnormalities playing a role in the myelodysplastic process have been difficult to identify. In this study, we analyzed the somatic mutations in the AML1/RUNX1 gene, which is a critical regulator of definitive hematopoiesis and the most frequent targets for translocation of acute myeloid leukemia (AML), in patients with MDS. We detected AML1 point mutations in 26 of 110 (23.6%) patients with refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEBt) and AML following MDS (defined these categories as MDS/AML). Among 22 patients with radiation-related (including 14 atomic bomb survivors) and/or therapy-related MDS/AML, 11 (50%) patients had the AML1 mutations mostly in N-terminal region. In contrast, 15 of 88 (17%) patients with sporadic MDS/AML showed the AML1 mutations equally in both N-terminal and C-terminal region. The MDS/AML patients with AML1 mutations had a significantly worse prognosis than those without AML1 mutations. Most of AML1 mutants lost trans-activation potential, regardless of their DNA binding potential. These data suggested that AML1 point mutation is one of the major driving forces of MDS/AML, and these mutations may represent a distinct clinicopathologic-genetic entity. | |||||
書誌情報 |
Acta medica Nagasakiensia 巻 50, 号 supl.1, p. 91-95, 発行日 2005-12 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00016055 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00508430 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
関係URI | ||||||
関連名称 | http://joi.jlc.jst.go.jp/JST.JSTAGE/amn/50.S91 | |||||
sortkey | ||||||
P00091-P00095 | ||||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Acta medica Nagasakiensia. 2005, 50(supl.1), p.91-95 |